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Recent advances in the therapeutic approach to the treat-ment of advanced non-small cell lung cancer (NSCLC)
have included the use of antiangiogenic agents, which target
various aspects of the vascular endothelial growth factor
(VEGF) pathway. The pivotal trial evaluated bevacizumab in
combination with carboplatin/paclitaxel (CbP) compared
with CbP alone.1 In that trial, bevacizumab added to CbP
leads to improved response rates and improved progression-
free and overall survival. Although certain toxicities were
also increased, for the appropriate patient, the potential ben-
efit of bevacizumab does outweigh its risk. Further improve-
ments in outcomes will require targeting of pathways impor-
tant in the pathogenesis of this disease.
Angiogenesis is a complex and a critical process play-
ing a key role in tumor growth. The fibroblastic growth factor
(FGF) family comprised a number of mitogenic polypeptides
(currently, there are 22 known members) involved in the
process of angiogenesis.2 Together with the four transmem-
brane tyrosine kinase receptors (FGF receptor [FGFR] 1–4),
evidence is accumulating suggesting an autocrine and para-
crine role in many solid tumors.3 FGF 2 (basic FGF) is consid-
ered a potent stimulator of angiogenesis binding to FGFR-1.
FGF-2 has been shown to exert its effect on endothelial cells
in a paracrine fashion as a consequence of secretion by tumor
or stromal cells.4 Evidence also suggests an autocrine role for
FGF-2 in endothelial cells.4,5 These observations make this
pathway and its ligands potential therapeutic targets in solid
tumors.
Coldren et al.6 used microarray gene expression profil-
ing to evaluate a number of NSCLC cell lines that were either
sensitive or refractory to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs). In NSCLC cell
lines relatively insensitive to EGFR TKIs, there was frequent
coexpression of FGFs (particularly FGR2 and FGF9) and
FGFRs (especially FGFR1 and 2).7 Specific silencing exper-
iments targeting FGF2 reduced anchorage-independent growth
of certain NSCLC cell lines that secrete FGF2 and coexpress
FGFR1 and/or FGFR2. RO4383596, a TKI that targets FGFRs
inhibited FGFR activity and proliferation and anchorage-inde-
pendent growth of NSCLC cell lines that coexpress FGF2 or
FGF9 and FGFRs. In contrast, RO4383596 did not influence
signal transduction or growth in NSCLC cell lines lacking
FGFs or FGFR2 expression. Taken together, these two re-
ports6,7 suggest that FGF2 and 9 and their respective FGFRs
may represent an autocrine growth loop that is active in
EGFR-insensitive NSCLC cell lines.
SUMMARY OF PRESENTATIONS
Brivanib is a small molecule tyrosine kinase inhibitor
of both VEGF and FGF signaling. It has shown antitumor
activity in lung, breast, and colon cancer xenograft models.8
Many tumors express elevated levels of FGF-2, which seems
to be associated with a poor prognosis in NSCLC and other
solid tumors.8 Brivanib has been shown to effectively inhibit
FGF-stimulated and FGF-dependent tumor and endothelial
cell lines.8 In a phase I trial, doses of brivanib of 180 to 1000
mg were studied in previously treated patients with cancer
(predominantly colorectal) with no prior exposure to antian-
giogenic agents.9 The maximum tolerated dose (MTD) was
800 mg daily with the most common toxicities consisting of
hypertension, fatigue, dizziness, and elevated AST/ALT. An-
titumor activity was observed with two patients having con-
firmed partial responses. There seemed to be an association
with FGF-2 expression and the activity of brivanib, but this
observation was based on a relatively small number of pa-
tients. A randomized discontinuation study is ongoing in multi-
ple tumor types attempting to test the hypothesis that tissue
FGF-2 expression may predict responsiveness to brivanib.
TKI258 is a small molecule inhibitor of multiple recep-
tor kinases including the FGFR1 to 3 and VEGF receptor-2.
This agent has shown antiproliferative effects in multiple cell
lines, which are driven by its target kinases.10,11 TKI258 has
been evaluated in at least 142 patients in both phase I and II
clinical trials. The maximum tolerated dose seems to be 500
mg on an intermittent schedule of 5 days on and 2 days off.
Dose-limiting toxicities in these trials consisted of fatigue,
hypertension and bradycardia; diarrhea, vomiting, and fa-
tigue, which seem to be the most frequent adverse events
reported. The clinical development of TKI258 has focused on
indications with FGFR gene mutation, amplification, and/or
protein overexpression such as the t(4:14) translocation in
multiple myeloma, FGFR-3 mutations in urothelial cancers,
and FGFR-1 amplification in breast cancer.
Tyro-3, Axl, and Mer share identical domain structure
and comprise the TAM receptor tyrosine kinases. TAM
signaling leads to angiogenesis, invasion, and enhanced met-
astatic potential and evasion of apoptosis.12 TAM receptor
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and ligand expression are clearly seen in NSCLC and corre-
lates with NSCLC cell invasiveness in vitro.13 Inhibition of
TAM receptors has been shown to increase sensitivity of both
leukemia and astrocytoma cells in vitro. This suggests the
TAM receptor may play a role in the mediation of chemore-
sistance.12 Early studies are ongoing in NSCLC.
SUMMARY
FGFs and FGFRs are potentially important targets in
NSCLC and other solid tumors. Well-designed clinical trials
that incorporate tumor-based correlative analyses interrogat-
ing the details of this pathway (overexpression of target or
ligand, receptor amplification, and/or mutation) in individual
patients are warranted based on the data summarized above.
Both single-agent use and combinations of anti-FGFs and/or
FGFR inhibitors with standard chemotherapy regimens and
other targeted therapies should be pursued.
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